NASDAQ:LRMR
Larimar Therapeutics, Inc. Stock Company Profile
$7.32
+0.200 (+2.81%)
At Close: May 13, 2024
Information
Three Bala Plaza East, Suite 506
Bala Cynwyd PA 19004
844 511 9056
www.larimartx.com
Industry: Biotechnology
Sector: Healthcare
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
